Sensitive method for determination of nicorandil in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.
A sensitive method for the determination of nicorandil, an anti-anginal drug, has been developed. The method involves solid-phase extraction of the drug and an internal standard using a Bond-Elut PH extraction column, liquid-liquid extraction with methyl acetate and dichloromethane, and reversed-phase high-performance liquid chromatography on a mu Bondapak C18 column with an ultraviolet detector. The limit of determination in plasma was 3 ng/ml and the intra-day coefficient of variation (n = 7) was less than 10%.
Assay Technology Laboratory, Development and Technology Division, Chugai Phamaceutical Co. Ltd., Tokyo, Japan.
M
M
Tanikawa
M
M
Uzu
Y
Y
Ohsawa
M
M
Fukushima
D000889:Anti-Arrhythmia Agents / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D015394:Molecular Structure; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000097:blood; D020108:Nicorandil; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet; D014665:Vasodilator Agents / Q000097:blood*
D000889:Anti-Arrhythmia Agents; D014665:Vasodilator Agents; D009536:Niacinamide; D020108:Nicorandil